Mariam Sarwar

Associate | She/Her/Hers

Overview

Mariam Sarwar is an associate in the firm’s Litigation and Trial group. Her work encompasses litigation matters across a variety of industries in the areas of complex commercial litigation, copyright and trademark infringement, unfair competition, trade secrets, false advertising, products liability, and consumer class actions. She has experience providing investigation and litigation issues analysis, as well as counseling on regulatory compliance. Mariam frequently advises clients on compliance, litigation, and enforcement matters involving the Food and Drug Administration. Her work helps clients navigate issues of product safety and recalls, advertising, marketing, labeling, and consumer protection.

Prior to joining the firm, Mariam served as a law clerk in the Los Angeles City Attorney’s Office’s Civil Litigation Department. She also worked as a research assistant for two years at Loyola Law School, assisting in developing course materials and with research and analysis on the use of survey evidence to prove consumer deception in U.S. state, agency, and federal court proceedings.

During law school, Mariam was as a senior production editor of the Loyola of Los Angeles Law Review. She was also a member of the Scott Moot Court Honors Board, the Alpha Sigma Nu National Honor Society, and the St. Thomas More Law Honor Society. 

Career & Education

|
    • Kalamazoo College, B.A., 2009
    • Loyola Law School, Los Angeles, J.D., 2019
    • Kalamazoo College, B.A., 2009
    • Loyola Law School, Los Angeles, J.D., 2019
    • California
    • California
    • Member, Pro Bono Advisory Council, Asian Americans Advancing Justice Southern California
    • Member, Pro Bono Advisory Council, Asian Americans Advancing Justice Southern California

Mariam's Insights

Client Alert | 3 min read | 01.11.24

FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements

In late December, the FDA released a guidance document that provides clarity for small businesses marketing direct-to-consumer (DTC) drug products on television or radio.  The Q&A followed the FDA’s November 2023 Final Rule amending DTC advertising regulations for prescription drugs. ...

Representative Matters

  • Representing an aviation industry client in a complex trade secrets case involving the development of hardware and software for avionics display units. 
  • Won summary judgment on behalf of a manufacturing company in a trade secrets litigation.
  • Represented an automobile company in various class action lawsuits alleging vehicle defects and obtained multiple dismissals of class action claims on motion to dismiss and summary judgment, including an affirmation of summary judgment dismissal by the Ninth Circuit Court of Appeal.
  • Represented a healthcare company in multiple products liability class action lawsuits, successfully obtaining favorable settlements and/or dismissals.
  • Represented a major beverage company in a class action lawsuit relating to allegedly misleading advertising based on ingredient claims.

Mariam's Insights

Client Alert | 3 min read | 01.11.24

FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements

In late December, the FDA released a guidance document that provides clarity for small businesses marketing direct-to-consumer (DTC) drug products on television or radio.  The Q&A followed the FDA’s November 2023 Final Rule amending DTC advertising regulations for prescription drugs. ...

|

Mariam's Insights

Client Alert | 3 min read | 01.11.24

FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements

In late December, the FDA released a guidance document that provides clarity for small businesses marketing direct-to-consumer (DTC) drug products on television or radio.  The Q&A followed the FDA’s November 2023 Final Rule amending DTC advertising regulations for prescription drugs. ...